|
02 Dec 2021 |
ITM and Navigo Proteins Announce Research Collaboration to Develop FAP-targeting Radionuclide Therapy to Address Solid Tumors
|
|
02 Dec 2021 |
UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease
|
|
02 Dec 2021 |
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
|
|
02 Dec 2021 |
Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals
|
|
30 Nov 2021 |
Ranok Therapeutics Announces Agreement with Pfizer on Targeted Protein Degradation
|
|
30 Nov 2021 |
Confo Therapeutics Enters Collaborative Agreement with Regeneron
|
|
30 Nov 2021 |
SciRhom augments seed financing to reach total funding of EUR 16 million
|
|
24 Nov 2021 |
Philogen announces new collaboration with Janssen to discover small molecule therapeutics
|
|
23 Nov 2021 |
Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases
|
|
23 Nov 2021 |
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
|
|
22 Nov 2021 |
Baidu Enters Into License Agreement With Sanofi to Enable Next-Generation mRNA Therapeutics and Vaccines
|
|
22 Nov 2021 |
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
|
|
22 Nov 2021 |
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
|
|
19 Nov 2021 |
Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
|
|
18 Nov 2021 |
Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform
|
|
18 Nov 2021 |
AVILAR THERAPEUTICS LAUNCHES WITH $60 MILLION SEED FINANCING TO PIONEER EXTRACELLULAR PROTEIN DEGRADATION Company founded and financed by RA Capital Management with
|
|
16 Nov 2021 |
SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences
|
|
16 Nov 2021 |
ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases
|
|
16 Nov 2021 |
Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases
|
|
16 Nov 2021 |
Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and Develop Novel SH2 Domain-Targeted Therapies for Cancer and Inflammatory Diseases; Appoints Dr. Nancy Whiting as CEO
|
|
12 Nov 2021 |
Organon to Acquire Forendo Pharma
|
|
10 Nov 2021 |
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
|
|
04 Nov 2021 |
Dalriada Drug Discovery Celebrates Client Dunad Therapeutics Billion Dollar Collaboration with Novartis
|
|
04 Nov 2021 |
Alpha Tau Announces Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)
|
|
02 Nov 2021 |
Dunad Therapeutics enters Strategic Collaboration with Novartis to Develop Next-generation Oral Targeted Protein Degrader Therapies
|
